EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Identifying clinically relevant subgroups of patients with knee pain flares for ibuprofen treatment: a secondary analysis

R U Sharma, J Runhaar, P K Bos, D M J Dorleijn, P J E Bindels, S M A Bierma-Zeinstra

Clinical Rheumatology · 2025

DOI: 10.1007/s10067-025-07539-0 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von R U Sharma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Practice, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. r.sharma@erasmusmc.nl. Hauptthemen laut MEDLINE: Ibuprofen, Osteoarthritis, Knee, Anti-Inflammatory Agents, Non-Steroidal, Knee Joint. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Arthritis Association, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to evaluate whether subgroups with more severe inflammatory symptoms during a knee pain flare benefited more from a high dose ibuprofen treatment than subgroups with less severe inflammatory symptoms.

Methods

This secondary analysis included adults with ≥ 1 flares of knee pain in the last year, who experienced a new episode within 24 h and randomized into two treatment groups of daily ibuprofen 1200 mg or 2400 mg for 5 days. A multilevel regression analysis was used to assess interaction effects between intervention groups and pre-defined subgroups, based on osteoarthritis related symptoms (severity of morning stiffness, swelling, and pain). The primary outcome was the difference in treatment effect between subgroups on pain severity (0–10 on the numeric rating scale (NRS)) after 5 days. Differences in treatment effect between subgroups after 3 days (NRS) and 5 days (Western Ontario and McMaster Universities Osteoarthritis (WOMAC) scale) were secondary outcomes.

Results

Participants ( N = 308) had a mean age of 52.4 ± 12.9 (SD) years with 41% female subjects. No significant interaction was found between the pre-defined subgroups and intervention groups on pain severity after day 5 (all p -values ≥ 0.28) or on the secondary outcomes (all p -values ≥ 0.38). Given the potential lack of power, the absolute and adjusted mean differences between treatment arms were compared for each subgroup; none of the differences reached clinical significance.

Conclusion

Between subgroups with more and less severe inflammatory symptoms during knee pain flares, no significant nor clinical benefit was found from a higher dose of ibuprofen compared to a lower dose. Keypoints • Despite the overall superiority of the higher dose, patients with severe inflammatory knee symptoms do not benefit more from an anti-inflammatory dose of ibuprofen than patients with less severe symptoms. • A higher dose of ibuprofen is not indicated for patients with severe inflammatory knee symptoms. • Given the heterogeneity among patients with knee osteoarthritis, potential subgroups should be explored in future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IbuprofenOsteoarthritis, KneeAnti-Inflammatory Agents, Non-SteroidalKnee JointArthralgiaHumansFemaleMaleMiddle AgedAdultPain MeasurementTreatment OutcomeSeverity of Illness IndexAgedSymptom Flare Up

Stichwörter der Autor:innen

IbuprofenKnee jointKnee painMorning stiffnessOsteoarthritisSwelling

Substanzen

IbuprofenAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of General Practice, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. r.sharma@erasmusmc.nl.
  • Department of General Practice, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Orthopedics & Sports Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Orthopedics and Traumatology, University Hospital Ghent, Ghent, Belgium.

Förderung

  • Dutch Arthritis Association
  • ZonMw

Zitieren

APA

Sharma, R. U., Runhaar, J., Bos, P. K., Dorleijn, D. M. J., Bindels, P. J. E., & Bierma-Zeinstra, S. M. A. (2025). Identifying clinically relevant subgroups of patients with knee pain flares for ibuprofen treatment: a secondary analysis. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07539-0

Vancouver

Sharma RU, Runhaar J, Bos PK, Dorleijn DMJ, Bindels PJE, Bierma-Zeinstra SMA. Identifying clinically relevant subgroups of patients with knee pain flares for ibuprofen treatment: a secondary analysis. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07539-0

BibTeX
@article{Sharma2025,
  author = {Sharma, R U and Runhaar, J and Bos, P K and Dorleijn, D M J and Bindels, P J E and Bierma-Zeinstra, S M A},
  title = {Identifying clinically relevant subgroups of patients with knee pain flares for ibuprofen treatment: a secondary analysis},
  journal = {Clinical Rheumatology},
  year = {2025},
  doi = {10.1007/s10067-025-07539-0}
}
Kostenlos starten →